<DOC>
	<DOCNO>NCT00786994</DOCNO>
	<brief_summary>In study impact Oleogel-S-10 versus placebo actinic keratoses treatment period 3 month test . Additionally , twice daily application test .</brief_summary>
	<brief_title>The Efficacy Tolerability Oleogel-S-10 Patients With Actinic Keratoses</brief_title>
	<detailed_description>Oleogel-S-10 show efficacy well tolerate two previous clinical trial . In second open label phase II trial efficacy Oleogel-S-10 alone similar compare invasive treatment cryotherapy . Response rate 85 % clear-ance 75 % lesion patient treat Oleogel-S-10 three month report . These encouraging result lead present randomize , multicenter , double blind phase II trial . The efficacy treatment shall test double blind placebo control ( petroleum jelly ) fashion order obtain reliable result plan phase III study .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Petrolatum</mesh_term>
	<criteria>At least two mild moderate actinic keratoses locate facial skin head ( except lip ) Actinic keratoses diameter 0,5 2 cm , definitely distinguish lesion display minimum distance 0,5 cm neighbor lesion evaluate histopathological grade 1 3 histologically proven AK within three month study entry prepare able give write informed consent â‰¥ 18 year age In case female : postmenopause define natural menopause menses &gt; 1 year ago serum FSH ( &gt; 20 IU/l ) E2 level postmenopausal range patient bilateral oophorectomy prepared comply study requirement , include follow : application OleogelS10 treatment area twice day 4 clinic visit prestudy , treatment , posttreatment , followup period pre posttreatment biopsy histological confirmation ( clearance ) AKdiagnosis Representative histologic slide tissue block ship Active immunosuppressive therapy data clinically significant , unstable , cardiovascular hematologic , hepatic , neurologic , renal , endocrine , collagenvascular , gastrointestinal abnormality diseases Note : Patients clinically stable medical condition include , limited , controlled hypertension , diabetes mellitus type II , hypercholesterolemia , osteoarthritis allow enter study know allergy excipient study drug dermatological disease and/or condition treatment surround area ( 3 cm distance treatment area ) may exacerbate treatment OleogelS10 cause difficulty examination active chemical dependency alcoholism , assess investigator pregnant lactate woman currently participate another clinical study complete another clinical study investigational drug within past 30 day receive topical treatment treatment area diclofenac gel , imiquimod 5FU within time period 1 month Concomitant existence nontreated ( nonexcised ) basal cell carcinoma , squamous cell carcinoma malignant melanoma Invasive tumor within treatment area , e.g . : merkel cell carcinoma , squamous cell carcinoma , basal cell carcinoma , latter accept completely surgically remove Note : A biopsy lesion within treatment surround area suggestive malignancy perform prestudy screen visit . If invasive SCC malignant condition confirm within treatment area , patient include study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Actinic Keratoses</keyword>
</DOC>